Suppr超能文献

哥斯达黎加和巴拿马的糖尿病二线药物处方模式:来自DISCOVER注册研究的证据

Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry.

作者信息

Chen-Ku Chih H, Grimaldo de Sucre Pilar, Vinocour Mary, Ramírez-Zamora Luis C, Andrés-Jiménez Fernando, Slon-Hitti Claudio, Cob Alejandro, Rodríguez Guiselle

机构信息

Endocrinology, Clinica Los Yoses, San Pedro, CRI.

Internal Medicine, Hospital Aquilino Tejeira, Penonomé, PAN.

出版信息

Cureus. 2021 Jun 30;13(6):e16060. doi: 10.7759/cureus.16060. eCollection 2021 Jun.

Abstract

AIM

This study aimed to describe the prescription patterns of second-line medications for patients with diabetes from selected centers in Costa Rica and Panama.

METHODS

DISCOVER is a registry of patients with type 2 diabetes switching from first- to second-line medications. We analyzed medication choice and the reasons to switch for each country.  Results: A total of 219 patients were included during 2014-2016, 127 in Costa Rica and 92 in Panama. The most frequently prescribed first-line medication was metformin, followed by sulphonylureas in Panama, and a combination of metformin and dipeptidyl peptidase-4 inhibitor (iDPP4) in Costa Rica. DPP4 inhibitors plus metformin was the most commonly prescribed second-line medication, followed by metformin combined with sodium-glucose transport protein-2 inhibitor (iSGLT2) in Costa Rica and iDPP4 in monotherapy in Panama. The main reason to switch being efficacy. When choosing the second-line medication, the main reasons behind the switch were efficacy, weight loss, and hypoglycemia risk in both countries (tolerability being also common in Panama).

CONCLUSIONS

According to the DISCOVER registry, in Costa Rica and Panama, efficacy is the most common reason to switch to second-line medication. Metformin plus iDPP4 was the most commonly prescribed agent.

摘要

目的

本研究旨在描述来自哥斯达黎加和巴拿马选定中心的糖尿病患者二线药物的处方模式。

方法

DISCOVER是一个2型糖尿病患者从一线药物转换为二线药物的登记系统。我们分析了每个国家的药物选择和换药原因。结果:2014年至2016年期间共纳入219例患者,其中哥斯达黎加127例,巴拿马92例。最常处方的一线药物是二甲双胍,在巴拿马其次是磺脲类药物,在哥斯达黎加是二甲双胍和二肽基肽酶-4抑制剂(DPP4i)的联合用药。DPP4抑制剂加二甲双胍是最常处方的二线药物,在哥斯达黎加其次是二甲双胍联合钠-葡萄糖转运蛋白-2抑制剂(SGLT2i),在巴拿马是DPP4i单药治疗。换药的主要原因是疗效。在选择二线药物时,两国换药背后的主要原因都是疗效、体重减轻和低血糖风险(耐受性在巴拿马也很常见)。

结论

根据DISCOVER登记系统,在哥斯达黎加和巴拿马,疗效是转换为二线药物最常见的原因。二甲双胍加DPP4i是最常处方的药物。

相似文献

本文引用的文献

1
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法: 。
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
8
Correlates of second-line type 2 diabetes medication selection in the USA.美国二线2型糖尿病药物选择的相关因素。
BMJ Open Diabetes Res Care. 2017 Sep 1;5(1):e000421. doi: 10.1136/bmjdrc-2017-000421. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验